Sparks commentary - Basilea Pharmaceutica

Healthcare

Sparks - Basilea Pharmaceutica

More on this equity
Basilea (SIX: BSLN) bags a US$2.5m milestone payment
Published by Arron Aatkar, PhD

Basilea has announced another milestone payment from its license partner Pfizer in the Asia Pacific region and China for strong Cresemba sales. Notably, the US$2.5m milestone payment is the first of 2025 in Asia Pacific and China, and twice the value of prior milestone payments from Pfizer for this region.

As a reminder, the license agreement between Basilea and Pfizer for Cresemba covers Europe (excluding the Nordic countries), China and 16 countries in the Asia Pacific region.

Latest

Healthcare | Comment

Cantargia (OMX: CANTA) enrols first patient in leukaemia study

Healthcare | Comment

Cantargia (OMX: CANTA) breast cancer study fully recruited

Industrials | Comment

NWF (LON: NWF) acquires Northern Energy Oil

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free